Tag Archives: Medicus Pharma

Philadelphia, Pennsylvania–(Newsfile Corp. – March 10, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (the “Company”) today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a “best-efforts” basis, at a price of $2.80 per unit. Each unit consisted of one common share of …

Philadelphia, Pennsylvania–(Newsfile Corp. – March 6, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (the “Company”) today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a “best-efforts” basis, at a price of $2.80 per unit. Each unit consists of one common share of the Company …

The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania–(Newsfile Corp. – March 6, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”) is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell …

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania–(Newsfile Corp. – February 27, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”) is pleased to announce that it has submitted a clinical design …

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania–(Newsfile Corp. – February 14, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”) is also pleased …

Medicus Pharma Ltd.’s shares will remain listed on the NASDAQ Capital Market Toronto, Ontario and Philadelphia, Pennsylvania–(Newsfile Corp. – February 11, 2025) – Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”) today announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, …